

## riTUXimab 375 mg/m<sup>2</sup> Combination Therapy-21 day

**Please reference appropriate NCCP regimen for details of the chemotherapy regimen being administered in combination with riTUXimab**

This regimen supersedes NCCP Regimen 00208 rituximab 375mg/m<sup>2</sup> therapy-follicular lymphoma as of February 2019

### INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	*Reimbursement Status
In combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory CD 20 positive patients with follicular lymphoma	C82	00542a	Hospital

*\*If the reimbursement status is not defined, the indication has yet to be assessed through the formal HSE reimbursement process.*

### TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

riTUXimab is administered in combination with chemotherapy on day one of a 21 day cycle for up to eight cycles or until disease progression or toxicity occurs.

Facilities to treat anaphylaxis MUST be present when therapy is administered

Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	riTUXimab	375 mg/m <sup>2</sup>	Iv infusion <sup>1</sup> Observe post infusion <sup>2</sup>	500ml NaCl 0.9% at a maximum rate of 400mg/hr <sup>1,3,4</sup>	Every 21 days for 8 cycles

<sup>1</sup>The recommended initial rate for infusion is 50 mg/hr; after the first 30 minutes, it can be escalated in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr. Subsequent infusions can be infused at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr. Development of an allergic reaction may require a slower infusion rate. See Hypersensitivity/Infusion reactions under Adverse Effects/Regimen Specific Complications below. Any deviation from the advised infusion rate should be noted in local policies

<sup>2</sup>Recommended Observation period: Patients should be observed for at least six hours after the start of the first infusion and for two hours after the start of the subsequent infusions for symptoms like fever and chills or other infusion-related symptoms. Any deviation should be noted in local policies.

<sup>3</sup>riTUXimab should be diluted to a final concentration of 1-4mg/ml.

#### <sup>4</sup> Rapid rate infusion schedule<sup>1</sup>

If patients did **not** experience a serious infusion related reaction with their first or subsequent infusions of a dose of riTUXimab administered over the standard infusion schedule, a more rapid infusion can be administered for second and subsequent infusions using the same concentration as in previous infusions. Initiate at a rate of 20% of the total dose for the first 30 minutes and then 80% of the dose for the next 60 minutes (total infusion time of 90 minutes). If the more rapid infusion is tolerated, this infusion schedule can be used when administering subsequent infusions. Patients who have clinically significant cardiovascular disease, including arrhythmias, or previous serious reactions to any prior biologic therapy or to riTUXimab, should not be administered the more rapid infusion.

### ELIGIBILITY:

- Indications as above

NCCP Regimen: RiTUXimab 375mg/m <sup>2</sup> combination therapy – 21 day	Published: 05/02/2019 Review: 05/02/2021	Version number: 1
Tumour Group: Lymphoma and myeloma NCCP Regimen Code: 00542	ISMO Contributor: Prof Maccon Keane	Page 1 of 5

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

*This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)*

- ECOG 0-2

## EXCLUSIONS:

- Hypersensitivity to riTUXimab or any of the excipients or to murine proteins.
- Active, severe infections (e.g. tuberculosis, sepsis and opportunistic infections)
- Patients in a severely immunocompromised state

## PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant medical oncologist or a consultant Haematologist working in the area of haematological malignancies

## TESTS:

### Baseline tests:

- FBC, renal and liver profile
- Uric acid, SPEP, DAT
- Cardiac function if clinically indicated
- Virology screen -Hepatitis B (HBsAg, HBcoreAb) & C, HIV

\*See Adverse Effects/Regimen Specific Complications re Hepatitis B Reactivation

### Regular tests:

- FBC, renal and liver profile
- LDH
- Cardiac function if clinically indicated

## Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

## DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.
- No dose modifications of riTUXimab are recommended

## Management of adverse events:

**Table 1: Dose modification schedule based on adverse events**

Adverse reactions	Discontinue	Recommended dose modification
Severe infusion related reaction (e.g dyspnoea, bronchospasm, hypotension or hypoxia) First occurrence		Interrupt infusion immediately. Evaluate for cytokine release/tumour lysis syndrome (appropriate laboratory tests) and pulmonary infiltration (chest x -ray). Infusion may be restarted on resolution of all symptoms, normalisation of laboratory values and chest x-ray findings at no more than one-half the previous rate.
Second occurrence	Consider discontinuing treatment	Consider coverage with steroids for those who are not already receiving steroids.
Mild or moderate infusion-related reaction		Reduce rate of infusion. The infusion rate may be increased upon improvement of symptoms

NCCP Regimen: RiTUXimab 375mg/m <sup>2</sup> combination therapy – 21 day	Published: 05/02/2019 Review: 05/02/2021	Version number: 1
Tumour Group: Lymphoma and myeloma NCCP Regimen Code: 00542	ISMO Contributor: Prof Maccon Keane	Page 2 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## SUPPORTIVE CARE:

**EMETOGENIC POTENTIAL:** Minimal (Refer to local policy)

### PREMEDICATIONS:

- Premedication consisting of an anti-pyretic and an anti-histamine should always be administered before each infusion of riTUXimab. Consider the inclusion of a glucocorticoid in patients not receiving glucocorticoid containing chemotherapy.

**Table 2: Suggested pre-medications prior to riTUXimab infusion:**

Drugs	Dose	Route
Paracetamol	1g	PO 60minutes prior to riTUXimab infusion
Chlorphenamine	10mg	IV bolus 60minutes prior to riTUXimab infusion
Hydrocortisone	100mg	IV bolus 60 minutes prior to riTUXimab infusion

### OTHER SUPPORTIVE CARE:

- Tumour lysis syndrome prophylaxis (Refer to local policy)
- Proton pump Inhibitor(Refer to local policy)
- PJP prophylaxis (Refer to local policy)
- **Anti-viral prophylaxis (Refer to local policy)**
- **Anti-fungal prophylaxis (Refer to local policy)**

## ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Hypersensitivity/Infusion Reactions:** Close monitoring is required throughout the first infusion. (Refer to local policy). RiTUXimab can cause allergic type reactions during the IV infusion such as hypotension, wheezing, rash, flushing, pruritis, sneezing, cough, fever or faintness.
- **Severe Cytokine Release syndrome:** Usually occurs within 1 to 2 hours of initiating the first infusion. This syndrome may be associated with some features of cytokine release/tumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphatemia, acute renal failure, elevated lactate dehydrogenase (LDH) and may be associated with acute respiratory failure and death.
  - Pulmonary interstitial infiltrates or oedema visible on chest x-ray may accompany acute respiratory failure.
  - For severe reactions, stop the infusion immediately and evaluate for tumour lysis syndrome and pulmonary infiltration. Aggressive symptomatic treatment is required. The infusion can be resumed at no more than one-half the previous rate once all symptoms have resolved, and laboratory values and chest x-ray findings have normalized.
- **Cardiac Disorders:** Patients with a history of cardiac disease and/or cardiotoxic chemotherapy should be monitored closely.

NCCP Regimen: RiTUXimab 375mg/m <sup>2</sup> combination therapy – 21 day	Published: 05/02/2019 Review: 05/02/2021	Version number: 1
Tumour Group: Lymphoma and myeloma NCCP Regimen Code: 00542	ISMO Contributor: Prof Maccon Keane	Page 3 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

- **Infections:** RiTUXimab should not be administered to patients with an active, severe infection. Caution should be exercised when considering the use of rituximab in patients with a history of recurring or chronic infections or with underlying conditions that may further predispose patients to serious infections. Consideration should be given to the use of antimicrobial prophylaxis.
- **Hepatitis B Reactivation:** This has been reported in patients receiving riTUXimab including fulminant hepatitis with fatal outcome. All patients should be tested for both HBsAg and HBcoreAb as per local policy. If either test is positive, such patients should be treated with lamivudine 100 mg/day orally, for the entire duration of chemotherapy and for six months afterwards. Such patients should also be monitored with frequent liver function tests and hepatitis B virus DNA at least every two months. If the hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to stopping chemotherapy.
- **Severe Mucocutaneous Reactions:** These include Steven Johnson syndrome and toxic epidermal necrolysis. Discontinue in patients who develop a severe mucocutaneous reaction. The safety of readministration has not been determined.
- **Progressive multifocal leukoencephalopathy (PML):** Use of riTUXimab may be associated with an increased risk of PML. Patients must be monitored for any new or worsening neurological symptoms. If a patient develops PML, the dosing of rituximab must be permanently discontinued.
- **Immunisations:**
  - The safety of immunisation with live viral vaccines following riTUXimab therapy has not been studied. Therefore vaccination with live virus vaccines is not recommended whilst on riTUXimab or whilst peripherally B cell depleted.
  - Patients treated with riTUXimab may receive non-live vaccinations

## DRUG INTERACTIONS:

- **Antihypertensives:** Additive effect of hypotension during riTUXimab infusion. Consider withholding antihypertensives 12 hours before and during riTUXimab infusion.
- Patients with human anti-mouse antibody or human anti-chimeric antibody (HAMA/HACA) titres may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
- Drug interaction databases should be consulted for more information.

## ATC CODE:

RiTUXimab                      L01XC02

## REFERENCES:

1. Byrd, JC et al Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) Blood 2003;101(1):6-14
2. Hochster H, Weller E, Gascoyne RD et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009; 27(10):1607-1614.
3. Coiffier B, Lepage E et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma. N Engl J Med 2002; 346 (4) 235-242.

NCCP Regimen: RiTUXimab 375mg/m <sup>2</sup> combination therapy – 21 day	Published: 05/02/2019 Review: 05/02/2021	Version number: 1
Tumour Group: Lymphoma and myeloma NCCP Regimen Code: 00542	ISMO Contributor: Prof Maccon Keane	Page 4 of 5

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

*This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)*

4. NCCP | RiTUXimab Rapid Infusion Rate Guidance | V1 2017 available at <https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/sactguidance/guidance%20on%20rituximab%20rapid%20infusion%20rate.pdf>
5. MabThera® Summary of Product Characteristics Accessed 01/11/2018 Available at: <https://www.medicines.org.uk/emc/product/3801/smpc>

Version	Date	Amendment	Approved By
1	05/02/2019		Prof Maccon Keane

Comments and feedback welcome at [oncologydrugs@cancercontrol.ie](mailto:oncologydrugs@cancercontrol.ie).

<sup>i</sup> ODMS – Oncology Drug Management System

CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes

Further details on the Cancer Drug Management Programme is available at;

<http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/>

<sup>ii</sup> The rapid infusion is an unlicensed means of administration of riTUXimab for the indications described above, in Ireland. Patient's should be informed of this and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or "off label" indications. Prescribers should be fully aware of their responsibility in communicating any relevant information to the patient and also ensuring that the unlicensed or "off label" means of administration has been acknowledged by the hospital's Drugs and Therapeutics Committee, or equivalent, in line with hospital policy.

NCCP Regimen: RiTUXimab 375mg/m <sup>2</sup> combination therapy – 21 day	Published: 05/02/2019 Review: 05/02/2021	Version number: 1
Tumour Group: Lymphoma and myeloma NCCP Regimen Code: 00542	ISMO Contributor: Prof Maccon Keane	Page 5 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		